Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis

Prevalence of antibiotic resistance in Helicobacter pylori : a systematic review and meta-analysis in World Health Organization regions

(2018) Alessia Savoldi et al.   GASTROENTEROLOGY

Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori

(2018) Min Li et al.   HELICOBACTER

Randomized controlled trial: PPI-based triple therapy containing metronidazole versus clarithromycin as first-line treatment for Helicobacter pylori in adolescents and young adults in Japan

(2018) Katushiro Mabe et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection

(2018) Mei-Jyh Chen et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Molecular Patterns of Resistance Among Helicobacter pylori Strains in South-Western Poland

(2018) Aldona Bińkowska et al.   Frontiers in Microbiology

Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori : A multicenter, prospective, randomized trial

(2017) Soichiro Sue et al.   HELICOBACTER

Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori

(2017) Teppei Adachi et al.   ONCOLOGY

Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-LineHelicobacter pyloriEradication: A Randomized Controlled Trial

(2017) Masafumi Maruyama et al.   Canadian Journal of Gastroenterology and Hepatology

Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype

(2016) T. Kagami et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Helicobacter pyloritherapy: a paradigm shift

(2016) David Y. Graham et al.   Expert Review of Anti-Infective Therapy

The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults

(2016) Carlo A. Fallone et al.   GASTROENTEROLOGY

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

(2016) P Malfertheiner et al.   GUT

Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial

(2016) Jyh-Ming Liou et al.   LANCET

Helicobacter pylori Primary Antibiotic Resistance in 2015 in Morocco: A Phenotypic and Genotypic Prospective and Multicenter Study

(2016) Najat Bouihat et al.   Microbial Drug Resistance

A Randomized Controlled Trial Comparing Sequential with Triple Therapy forHelicobacter pyloriin an Aboriginal Community in the Canadian North

(2016) Amy L Morse et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: the global emergence ofHelicobacter pyloriantibiotic resistance

(2015) I. Thung et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Meta-analysis in clinical trials revisited

(2015) Rebecca DerSimonian et al.   Contemporary Clinical Trials

Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey

(2015) Gokhan Gungor et al.   DIGESTION

Molecular Approaches to Identify Helicobacter pylori Antimicrobial Resistance

(2015) Francis Mégraud et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

How to Effectively Use Bismuth Quadruple Therapy

(2015) David Y. Graham et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Concomitant therapy achieved the best eradication rate forHelicobacter pyloriamong various treatment strategies

(2015) Hyun Jeong Lee   WORLD JOURNAL OF GASTROENTEROLOGY

Strategy for the Treatment of Helicobacter pylori Infection

(2014) Seiji Shiota et al.   CURRENT PHARMACEUTICAL DESIGN

Efficacy of TailoredHelicobacter pyloriEradication Treatment Based on Clarithromycin Susceptibility and Maintenance of Acid Secretion

(2014) Mitsushige Sugimoto et al.   HELICOBACTER

Clarithromycin Versus Metronidazole as First-line Helicobacter pylori Eradication

(2014) Toshihiro Nishizawa et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Rational Helicobacter pylori Therapy: Evidence-Based Medicine Rather Than Medicine-Based Evidence

(2013) David Y. Graham et al.   Clinical Gastroenterology and Hepatology

Meta-Analysis of Bismuth Quadruple Therapy versus Clarithromycin Triple Therapy for Empiric Primary Treatment ofHelicobacter pyloriInfection

(2013) Marino Venerito et al.   DIGESTION

Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance

(2013) Javier Molina–Infante et al.   GASTROENTEROLOGY

Isolation of Helicobacter pylori in gastric mucosa and susceptibility to five antimicrobial drugs in Southern Chile

(2012) Laura Otth et al.   BRAZILIAN JOURNAL OF MICROBIOLOGY

Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori

(2012) A. Cosme et al.   CLINICAL MICROBIOLOGY AND INFECTION

Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: Result of the HPFEZ randomised study

(2012) Mounia Lahbabi et al.   Clinics and Research in Hepatology and Gastroenterology

Role of Omeprazole Dosage and Cytochrome P450 2C19 Genotype in Patients Receiving Omeprazole-Amoxicillin Dual Therapy forHelicobacter pyloriEradication

(2011) Jyh-Chin Yang et al.   PHARMACOTHERAPY

Helicobacter pylori treatment in the era of increasing antibiotic resistance

(2010) D. Y. Graham et al.   GUT

Primary resistance to clarithromycin, metronidazole and amoxicillin of Helicobacter pylori isolated from Tunisian patients with peptic ulcers and gastritis: a prospective multicentre study

(2010) Khansa Ben Mansour et al.   Annals of Clinical Microbiology and Antimicrobials

Smoking and drinking habits are important predictors of Helicobacter pylori eradication

(2009) D Namiot et al.   Advances in Medical Sciences

Empiric Quadruple vs. Triple Therapy for Primary Treatment of Helicobacter pylori Infection: Systematic Review and Meta-Analysis of Efficacy and Tolerability

(2009) Jay Luther et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Helicobacter pyloriEradication Therapy Success Regarding Different Treatment Period Based on Clarithromycin or Metronidazole Triple-Therapy Regimens

(2009) Tajana Filipec Kanizaj et al.   HELICOBACTER

Ulcusheilung durch Helicobacter-pylori-Eradikation: Genügt eine Woche Therapie?

(2008) J. Labenz et al.   DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT

Tailored eradication therapy based on fecalHelicobacter pyloriclarithromycin sensitivities

(2008) Takashi Kawai et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY